Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that a poster entitled "A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo", will be presented today at the American Association for Cancer Research (AACR) Annual Meeting by Fredrik Öberg, CSO at Medivir. Fostroxacitabine bralpamide (fostrox) is an orally administered liver-targeted prodrug currently undergoing a phase 1/2a